SamJB
Well-Known Member
- Messages
- 1,857
- Type of diabetes
- Type 1
- Treatment type
- Pump
There are a few reasons why pharma companies don't release all data, most of them down to commercial reasons. They don't want to give their competitors any intelligence. Sounds fair enough to me. People forget sometimes that these are private companies; they need to make money. It's papers like the Mail and Express that are up in arms about the cost of some novel cancer treatments. What they don't report is that it costs $1bn and 1 decade to bring a drug to market. Regrettably, pharma companies are not charities, if they don't make money, there will be no drugs at all. Say goodbye to controlling diabetes.
Secondly, studies might be flawed, they might not show any trends, there might be a large number of deaths (unrelated to the drug, but related to the disease), there may have been funding cuts, there might have been too many protocol deviations, or it might have been decided half way through the trial that for whatever reason it will be discontinued.
So, I don't believe that there are sinister reasons why data is not being released. If a trial has shown up intolerable, or life threatening adverse events, then the regulators would've know about it and the scientists would not have exposed patients to it.
Secondly, studies might be flawed, they might not show any trends, there might be a large number of deaths (unrelated to the drug, but related to the disease), there may have been funding cuts, there might have been too many protocol deviations, or it might have been decided half way through the trial that for whatever reason it will be discontinued.
So, I don't believe that there are sinister reasons why data is not being released. If a trial has shown up intolerable, or life threatening adverse events, then the regulators would've know about it and the scientists would not have exposed patients to it.